Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Cancer statistics, 2013

Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Liu, J. F., & Matulonis, U. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0515-z · Cited by 27

Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway

Liu, Y., Mei, Y., Tian, Z., Long, J., Luo, C., & Zhou, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489418 · Cited by 27

FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism

Miao, H., Meng, H., Zhang, Y., Chen, T., Zhang, L., & Cheng, W. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01263-z · Cited by 26

Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy

Zhou, Q., Tu, X., Hou, X., Yu, J., Zhao, F., Huang, J., Kloeber, J. A., Olson, A., Gao, M., Luo, K., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101085 · Cited by 26

USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity

Nespolo, A., Stefenatti, L., Pellarin, I., Gambelli, A., Vinciguerra, G. L. R., Karimbayli, J., Barozzi, S., Orsenigo, F., Spizzo, R., Nicoloso, M. S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp6567 · Cited by 26

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas

Milanesio, M. C., Giordano, S., & Valabrega, G. (2020) · Cancers · doi:10.3390/cancers12051315 · Cited by 26

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Lampert, E. J., Cimino‐Mathews, A., Lee, J. S., Nair, J. R., Lee, M.-J., Yuno, A., An, D., Trepel, J. B., Ruppin, E., & Lee, J.-M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000516 · Cited by 26

Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer

Wallace-Povirk, A., Hou, Z., Nayeen, M. J., Gangjee, A., & Matherly, L. H. (2021) · Cancers · doi:10.3390/cancers14010191 · Cited by 26

Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary

Fusco, M. J., Knepper, T. C., Balliu, J., Cueto, A. D., Laborde, J., Hooda, S. M., Brohl, A. S., Bui, M. M., & Hicks, J. K. (2022) · The Oncologist · doi:10.1093/oncolo/oyab014 · Cited by 26

Dose-Dense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: A Meta-Analysis

Nguyen, T. V., Winterman, S., Playe, M., Benbara, A., Zelek, L. H., Pamoukdjian, F., & Bousquet, G. (2021) · Cancers · doi:10.2139/ssrn.3844912 · Cited by 26

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells

Chiappa, M., Guffanti, F., Anselmi, M., Lupi, M., Panini, N., Wiesmüller, L., & Damia, G. L. M. (2022) · Cancers · doi:10.3390/cancers14071807 · Cited by 26

Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer

Oda, K., Aoki, D., Tsuda, H., Nishihara, H., Aoyama, H., Inomata, H., Shimada, M., & Enomoto, T. (2022) · Cancer Science · doi:10.1111/cas.15518 · Cited by 26

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer

Coelho, R., Tozzi, A., Disler, M., Lombardo, F. C., Fedier, A., López, M. N., Freuler, F., Jacob, F., & Heinzelmann-Schwarz, V. A. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05347-x · Cited by 26

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

Shah, J., Pueschl, D., Wubbenhorst, B. S., Fan, M., Pluta, J. B., D'Andrea, K. P., Hubert, A. P., Shilan, J. S., Zhou, W., Kraya, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34523-y · Cited by 26

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

Tsang, E. S., Csizmók, V., Williamson, L. M., Pleasance, E., Topham, J. T., Karasinska, J. M., Titmuss, E., Schrader, K. A., Yip, S. S. F., Tessier‐Cloutier, B., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00368-x · Cited by 26

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

Pratz, K. W., Koh, B. D., Patel, A. G., Flatten, K. S., Poh, W., Herman, J. G., Dilley, R. L., Harrell, M. I., Smith, B. D., Karp, J. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2351 · Cited by 26

Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?

Tomao, F., Santangelo, G., Musacchio, L., Donato, V. D., Fischetti, M., Giancotti, A., Perniola, G., Petrella, M. C., Monti, M., Palaia, I., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29440 · Cited by 26

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases

Ekstrom, T. L., Pathoulas, N. M., Huehls, A. M., Kanakkanthara, A., & Karnitz, L. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1099 · Cited by 25

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination

Brown, V. E., Moore, S. L., Chen, M., House, N. C. M., Ramsden, P., Wu, H., Ribich, S. A., Grassian, A. R., & Choi, Y. J. (2023) · NAR Cancer · doi:10.1093/narcan/zcad039 · Cited by 25

CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer

Orhan, E., Velázquez, C., Tabet, I., Fenou, L., Rodier, G., Orsetti, B., Jacot, W., Sardet, C., & Theillet, C. G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216820 · Cited by 25

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

Nunes, M., Bartosch, C., Abreu, M. H., Richardson, A., Almeida, R., & Ricardo, S. A. V. (2024) · Cells · doi:10.3390/cells13090786 · Cited by 26

53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer

Sun, Y., Patterson-Fortin, J., Han, S., Li, Z., Nowicka, Z., Hirohashi, Y., Kilgas, S., Yi, J. K., Spektor, A., Fendler, W. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50999-2 · Cited by 25

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue

de Jonge, M. M., Ruano, D., van Eijk, R., van der Stoep, N., Nielsen, M., Wijnen, J., ter Haar, N. T., Baalbergen, A., Bos, M. E. M. M., Kagie, M. J., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.005 · Cited by 27

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

Kim, D., Chung, H., Liu, W., Jeong, K., Ozmen, T. Y., Ozmen, F., Rames, M. J., Kim, S., Guo, X., Jameson, N. M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00787-4 · Cited by 24

Multi‐omics in high‐grade serous ovarian cancer: Biomarkers from genome to the immunome

Clifford, C., Vitkin, N., Nersesian, S., Reid‐Schachter, G., Francis, J., & Koti, M. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.12975 · Cited by 24

The Application of Patient-Derived Xenograft Models in Gynecologic Cancers

Jiang, W., Xie, S., Liu, Y., Zou, S., & Zhu, X. (2020) · Journal of Cancer · doi:10.7150/jca.46145 · Cited by 24

LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365

Yuan, J., Yi, K., & Yang, L. (2021) · Medicine · doi:10.1097/md.0000000000023423 · Cited by 24

CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents

Oyama, Y., Shigeta, S., Tokunaga, H., Tsuji, K., Ishibashi, M., Shibuya, Y., Shimada, M., Yasuda, J., & Yaegashi, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251079 · Cited by 24

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors

Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102298 · Cited by 22

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

Li, N., Liu, Q., Tian, Y., & Wu, L. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e86 · Cited by 24

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

Nishikawa, T., Matsumoto, K., Tamura, K., Yoshida, H., Imai, Y., Miyasaka, A., Onoe, T., Yamaguchi, S., Shimizu, C., Yonemori, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13307 · Cited by 24

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Gockley, A. A., Kolin, D. L., Awtrey, C. S., Lindeman, N. I., Matulonis, U. A., & Konstantinopoulos, P. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.028 · Cited by 24

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

Labrie, M., Kim, T., Ju, Z., Lee, S., Zhao, W., Fang, Y., Lu, Y., Chen, K., Ramirez, P. T., Frumovitz, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26947 · Cited by 24

Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma

Matsushita, H., Hasegawa, K., Oda, K., Yamamoto, S., Asada, K., Karasaki, T., Yabuno, A., Nishijima, A., Nejo, T., Kobayashi, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000375 · Cited by 24

Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma

Dai, W., Chung, D. L., Chow, L. K.-Y., Yu, V. Z., Lei, L. C., Leong, M. M., Chan, C. K.-C., Ko, J. M. Y., & Lung, M. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2854 · Cited by 24

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy

Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1874-9 · Cited by 23

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?

Funingana, I.-G., Reinius, M. A. V., Petrillo, A., Ang, J. E., & Brenton, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.008 · Cited by 23

TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer

Zorea, J., Motro, Y., Mazor, R. D., Carmi, Y. K., Shulman, Z., Mahajna, J. A., Moran‐Gilad, J., & Elkabets, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02680-7 · Cited by 24

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

Stiegeler, N., Garsed, D. W., Au‐Yeung, G., Bowtell, D. D. L., Heinzelmann-Schwarz, V. A., & Zwimpfer, T. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387281 · Cited by 23

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

Kanakkanthara, A., Hou, X., Ekstrom, T. L., Zanfagnin, V., Huehls, A. M., Kelly, R. L., Ding, H., Larson, M. C., Vasmatzis, G., Oberg, A. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0732 · Cited by 23

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer

Galland, L., Roussot, N., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., Réda, M., Albuisson, J., Arnould, L., et al. (2023) · Cancers · doi:10.3390/cancers15041299 · Cited by 23

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer

Fountzilas, E., Papadopoulou, K., Chatzikonstantinou, T., Karakatsoulis, G., Constantoulakis, P., Tsantikidi, A., Tsaousis, G., Karageorgopoulou, S., Koumarianou, A. A., Mauri, D., et al. (2023) · Cancers · doi:10.3390/cancers15235525 · Cited by 23

Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer

Wehn, A. K., Qiu, P., Lunceford, J. K., Yarunin, A., Cristescu, R., Liu, L., Roessler, K., Bilke, S., Day, J. R., Timms, K. M., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.01.016 · Cited by 23

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial

Roma, C., Abate, R. E., Sacco, A., Califano, D., Arenare, L., Bergantino, F., Pisano, C., Cecere, S. C., Scambia, G., Lorusso, D., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114127 · Cited by 23

Dormant origin firing promotes head-on transcription-replication conflicts at transcription termination sites in response to BRCA2 deficiency

Goehring, L. J., Keegan, S., Lahiri, S., Xia, W., Kong, M., Jiménez-Sáinz, J., Gupta, D., Drapkin, R., Jensen, R. B., Smith, D. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48286-1 · Cited by 25

The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival

Hacker, K., Bolland, D. E., Tan, L., Saha, A. K., Niknafs, Y. S., Markovitz, D. M., & McLean, K. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.005 · Cited by 23

Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer

Veneris, J. T., Huang, L., Churpek, J. E., Conzen, S. D., & Fleming, G. F. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000101 · Cited by 23

Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making

Jorge, S., McFaddin, A. S., Doll, K. M., Pennington, K. P., Norquist, B. M., Bennett, R. L., Pritchard, C. C., & Swisher, E. M. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.010 · Cited by 23

Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer

Leitner, K., Tsibulak, I., Wieser, V. E., Knoll, K., Reimer, D., Marth, C., Fiegl, H., & Zeimet, A. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77532-x · Cited by 24

Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images

Mingzhu, L., Ge, Y., Li, M.-R., & Wei, W. (2021) · BMC Medical Imaging · doi:10.1186/s12880-021-00711-3 · Cited by 23

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

Ray, A., & Opyrchal, M. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00582-5 · Cited by 23

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy

Kawachi, A., Yamashita, S., Okochi‐Takada, E., Hirakawa, A., Tsuda, H., Shimomura, A., Kojima, Y., Yonemori, K., Fujiwara, Y., Kinoshita, T., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05647-w · Cited by 22

DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?

Stefanou, D. T., Souliotis, V. L., Zakopoulou, R., Liontos, M., & Bamias, A. (2021) · Biomedicines · doi:10.3390/biomedicines10010082 · Cited by 23

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

Pacheco-Barcía, V., Martín, A. J. M., Castro, E., Ballesteros, A. I., Marquina, G., González-Díaz, I., Colomer, R., & Romero-Laorden, N. (2022) · Cancers · doi:10.3390/cancers14122950 · Cited by 23

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer

van Wagensveld, L., van Baal, J. O. A. M., Timmermans, M., Gaillard, D., Borghuis, L., Coffelt, S. B., Rosenberg, E. H., Lok, C. A. R., Nijman, H. W., Kooreman, L. F. S., et al. (2022) · Cancers · doi:10.3390/cancers14235965 · Cited by 22

Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins

McGrail, D. J., Li, Y., Smith, R. S., Feng, B., Dai, H., Hu, L., Dennehey, B. K., Awasthi, S., Mendillo, M. L., Sood, A. K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101255 · Cited by 24

An E3 ubiquitin ligase localization screen uncovers DTX2 as a novel ADP-ribosylation-dependent regulator of DNA double-strand break repair

Djerir, B., Marois, I., Dubois, J.-C., Findlay, S., Morin, T., Senoussi, I., Cappadocia, L., Orthwein, A., & Maréchal, A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107545 · Cited by 22

Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition

Mattoo, A. R., Joun, A., & Jessup, J. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0650 · Cited by 23

Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high‐grade serous ovarian cancer

Benvenuto, G., Todeschini, P., Paracchini, L., Calura, E., Fruscio, R., Romani, C., Beltrame, L., Martini, P. G. V., Ravaggi, A., Ceppi, L., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32935 · Cited by 22

Opening the Black Box: Spatial Transcriptomics and the Relevance of Artificial Intelligence–Detected Prognostic Regions in High-Grade Serous Carcinoma

Laury, A. R., Zheng, S., Aho, N., Fallegger, R., Hänninen, S. M., Sáez-Rodríguez, J., Tanevski, J., Youssef, O., Tang, J. P., & Carpén, O. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100508 · Cited by 21

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells

Gao, J., Wang, Z., Fu, J., Jisaihan, A., Ohno, Y., & Xu, C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10367 · Cited by 21

GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing

Chen, D., Shao, M., Meng, P., Wang, C., Li, Q., Cai, Y., Song, C., Wang, X., & Shi, T. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04487-9 · Cited by 21

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Park, J., Lim, M. C., Lee, J. K., Jeong, D. H., Kim, S. I., Choi, M. C., Kim, B., & Lee, J. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e12 · Cited by 21

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

Quesada, S., Fabbro, M., & Solassol, J. (2022) · Cancers · doi:10.3390/cancers14051132 · Cited by 21

EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

Konstantinopoulos, P. A., González-Martı́n, A., Cruz, F. M., Friedlander, M. L., Glasspool, R. M., Lorusso, D., Marth, C., Monk, B. J., Kim, J., Hinson, P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0666 · Cited by 21

Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer

Galhenage, P. M., Zhou, Y., Perry, E., Loc, B., Fietz, K., Iyer, S., Reinhardt, F., Silva, T. D., Botchkarev, V. A., Chen, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113144 · Cited by 21

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

Pozzorini, C., Andre, G., Coletta, T., Buisson, A., Bieler, J., Ferrer, L., Kempfer, R., Saintigny, P., Harlé, A., Vacirca, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101344 · Cited by 22

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts

Guffanti, F., Fratelli, M., Ganzinelli, M., Bolis, M., Ricci, F., Bizzaro, F., Chilà, R., Sina, F. P., Fruscio, R., Lupia, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25185 · Cited by 21

Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival

Engqvist, H., Parris, T. Z., Rönnerman, E. W., Forsberg, E. M. V., Biermann, J., Mateoiu, C., Sundfeldt, K., Kovács, A., Karlsson, P., & Helou, K. (2018) · Oncotarget · doi:10.18632/oncotarget.26225 · Cited by 21

Current First-line Therapy for Ovarian Cancer: A Comprehensive Review

Pierce, S. R., & Clark, L. H. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000613 · Cited by 17

Olaparib in the Treatment of Ovarian Cancer

Washington, C. R., Richardson, D. L., & Moore, K. N. (2019) · Future Oncology · doi:10.2217/fon-2019-0271 · Cited by 21

Genomic Scar Signatures Associated with Homologous Recombination Deficiency Predict Adverse Clinical Outcomes in Patients with Ovarian clear Cell Carcinoma

Chao, A., Lai, C.-H., Wang, T.-H., Jung, S.-M., Lee, Y.-S., Chang, W.-Y., Yang, L.-Y., Ku, F.-C., Huang, H.-J., Chao, A.-S., et al. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1643-8 · Cited by 20

PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials

Crafton, S., Bixel, K. L., & Hays, J. L. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.003 · Cited by 20

Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review

Teixeira, L. A., & dos Reis, F. J. C. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206276 · Cited by 20

RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status

Sinha, A., Saleh, A. J., Endersby, R., Yuan, S. H., Chokshi, C., Brown, K. R., Kuzio, B., Kauppinen, T. M., Singh, S. K., Baker, S. J., et al. (2020) · Cancers · doi:10.3390/cancers12113178 · Cited by 20

Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer

Tang, L., Wu, W., Zhang, C., Shi, Z., Chen, D., Zhai, X., & Jiang, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105026 · Cited by 20

Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

Franz, A., Coscia, F., Shen, C., Charaoui, L., Mann, M., & Sander, C. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00886-x · Cited by 20

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

Liu, H., Zhang, Z., Chen, L., Pang, J., Wu, H., & Liang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.798173 · Cited by 20

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

Liu, Y., Wang, W., Yin, R., Zhang, Y., Zhang, Y., Zhang, K., Pan, H., Wang, K., Lou, G., Li, G., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03046-8 · Cited by 20

DNA damage repair functions and targeted treatment in breast cancer

He, C., Kawaguchi, K., & Toi, M. (2020) · Breast Cancer · doi:10.1007/s12282-019-01038-2 · Cited by 20

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer

Nakamura, K., Aimono, E., Tanishima, S., Imai, M., Nagatsuma, A. K., Hayashi, H., Yoshimura, Y., Nakayama, K., Kyo, S., & Nishihara, H. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00368 · Cited by 20

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Jang, A., Sartor, O. A., Barata, P. C., & Paller, C. J. (2020) · Cancers · doi:10.3390/cancers12113467 · Cited by 20

DNA Polymerase θ: A Cancer Drug Target with Reverse Transcriptase Activity

Chen, X. S., & Pomerantz, R. T. (2021) · Genes · doi:10.3390/genes12081146 · Cited by 20

Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential

Bürkel, F., Jost, T., Hecht, M., Heinzerling, L., Fietkau, R., & Distel, L. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239321 · Cited by 19

Molecular Pathology of Ovarian Epithelial Neoplasms

Ordulu, Z., Watkins, J. C., & Ritterhouse, L. L. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.006 · Cited by 19

Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

Li, W., Gao, L., Yi, X., Shi, S., Huang, J., Shi, L. M., Zhou, X., Wu, L., & Ying, J. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.02.004 · Cited by 19

The Landscape of PARP Inhibitors in Solid Cancers

Muzzana, M., Broggini, M., & Damia, G. L. M. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s499226 · Cited by 19

Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination

Zhai, B., Steinø, A., Bacha, J., Brown, D., & Daugaard, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1069-9 · Cited by 19

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients

Li, Y., Zhang, X., Gao, Y., Shang, C., Yu, B., Wang, T., Su, J., Huang, C., Wu, Y., Guo, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625866 · Cited by 19

Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers

Farmanbar, A., Firouzi, S., KNELLER, R. W., & Khiabanian, H. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03259-0 · Cited by 19

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!

Magliacane, G., Brunetto, E., Calzavara, S., Bergamini, A., Pipitone, G. B., Marra, G., Redegalli, M., Grassini, G., Rabaiotti, E., Taccagni, G., et al. (2022) · Cancers · doi:10.3390/cancers15010043 · Cited by 19

HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data

Abbasi, A., Steele, C. D., Bergstrom, E. N., Khandekar, A., Farswan, A., McKay, R. R., Pillay, N., & Alexandrov, L. B. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2639 · Cited by 18

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

Thaker, P. H., Richardson, D. L., Hagemann, A. R., Holloway, R. W., Reed, M., Bergman, M. K., Pothuri, B., DePasquale, S. E., Scalici, J. M., Bregar, A. J., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.04.578 · Cited by 18

Frontline therapy of ovarian cancer: trials and tribulations

Volpe, J., Filipi, J., Cooper, O. R., & Penson, R. T. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000434 · Cited by 18

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

Wang, Y., Ren, F., Song, Z., Wang, X., Zhang, C., & Ouyang, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01204 · Cited by 18

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

Xu, Q. S., & Li, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743073 · Cited by 18

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

Kahn, R. M., Selenica, P., Boerner, T., Roche, K. L., Xiao, Y., Sia, T., Maio, A., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.11.019 · Cited by 18

Heterogeneity of computational pathomic signature predicts drug resistance and intra-tumor heterogeneity of ovarian cancer

Zhu, Q., Dai, H., Qiu, F., Lou, W., Wang, X., Deng, L., & Shi, C. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101855 · Cited by 18

Utilizing nullomers in cell-free RNA for early cancer detection

Montgomery, A., Tsiatsianis, G. C., Mouratidis, I., Chan, C. S. Y., Αθανασίου, Μ., Papanastasiou, A. D., Kantere, V., Syrigos, N., Vathiotis, I. A., Syrigos, K., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00741-3 · Cited by 20

How to measure homologous recombination deficiency in ovarian cancer

Marchetti, C., & McNeish, I. A. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0034 · Cited by 2

Homologous Recombination and BRCA Genes in Ovarian Cancer

Liu, J. F., & Konstantinopoulos, P. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00006-9 · Cited by 1

Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data

Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 40

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction

Chiang, Y., Lin, P., & Cheng, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675972 · Cited by 38

Abstract IA14: Exploiting the translational and functional opportunities for homologous recombination deficiency

Edmondson, R. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ovca13-ia14